These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33084153)

  • 21. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
    Thompson KM; Kalkowska DA
    Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293
    [No Abstract]   [Full Text] [Related]  

  • 23. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
    Thompson KM; Kalkowska DA; Badizadegan K
    Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling the dynamics of oral poliovirus vaccine cessation.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A vision of a world without polio: the OPV cessation strategy.
    Heymann DL; Sutter RW; Aylward RB
    Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
    Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Jan; 46(RR-3):1-25. PubMed ID: 9026708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polio endgame: the global introduction of inactivated polio vaccine.
    Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
    Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The risks, costs, and benefits of possible future global policies for managing polioviruses.
    Thompson KM; Tebbens RJ; Pallansch MA; Kew OM; Sutter RW; Aylward RB; Watkins M; Gary HE; Alexander J; Jafari H; Cochi SL
    Am J Public Health; 2008 Jul; 98(7):1322-30. PubMed ID: 18511720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
    Duintjer Tebbens RJ; Thompson KM
    BMC Infect Dis; 2015 Sep; 15():390. PubMed ID: 26404780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Towards global poliomyelitis eradication: the successes and challenges for a developed country.
    Wood N; Thorley B
    J Paediatr Child Health; 2003 Dec; 39(9):647-50. PubMed ID: 14629492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.
    Thompson KM; Duintjer Tebbens RJ
    Medscape J Med; 2008; 10(8):190. PubMed ID: 18924642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio.
    Hampton LM; du Châtellier GM; Fournier-Caruana J; Ottosen A; Rubin J; Menning L; Farrell M; Shendale S; Patel M
    J Infect Dis; 2017 Jul; 216(suppl_1):S217-S225. PubMed ID: 28838193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eradication of poliomyelitis in the United States.
    Nathanson N
    Rev Infect Dis; 1982; 4(5):940-50. PubMed ID: 7146731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
    Immunization Systems Management Group of the Global Polio Eradication Initiative
    MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polio endgame: Lessons for the global rotavirus vaccination program.
    Jiang B; Patel M; Glass RI
    Vaccine; 2019 May; 37(23):3040-3049. PubMed ID: 31027927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.